Soligenix
SNGX
#10223
Rank
HK$0.12 B
Marketcap
HK$12.53
Share price
-1.23%
Change (1 day)
-49.67%
Change (1 year)

Revenue for Soligenix (SNGX)

Revenue in 2025 (TTM): N/A

In 2024 the company made a revenue of HK$0.9 Million a decrease over the revenue in the year 2023 that were of HK$2 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Soligenix from 1998 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) N/A-100%
2024 HK$0.9 M-54.77%
2023 HK$2 M2.83%
2022 HK$1.95 M651.11%
2021 HK$0.26 M-98.26%
2020 HK$14.96 M-40.24%
2019 HK$25.04 M-19.35%
2018 HK$31.05 M-8.05%
2017 HK$33.77 M-58.32%
2016 HK$81.02 M19.22%
2015 HK$67.96 M24.41%
2014 HK$54.62 M118.51%
2013 HK$25 M2.57%
2012 HK$24.37 M-59.05%
2011 HK$59.51 M292.67%
2010 HK$15.15 M-30.58%
2009 HK$21.83 M22.31%
2008 HK$17.85 M81.95%
2007 HK$9.81 M-45.46%
2006 HK$17.98 M-22.03%
2005 HK$23.07 M
1999 HK$0 M-100%
1998 HK$3.09 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Cleveland BioLabs
CBLI
HK$4.91 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
HK$5.84 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$369.96 BN/A๐Ÿ‡ซ๐Ÿ‡ท France
Pfizer
PFE
HK$488.76 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
HK$717.34 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
HK$0.62 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
HK$1.75 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$130.59 BN/A๐Ÿ‡ฎ๐Ÿ‡ฑ Israel